Biotech Values

[vieuxblue]

Re: TEVA--Dew, did you sell because you had reached a predetermined sell point or because you thought that TEVA has risen quickly and might not be able to maintain the pace in the short term?

I'm inclined to hold for the mid- to long-term, especially as the pressure will build in the U.S. for more generics as the new Medicare Part D kicks in, which directly punishes seniors for purchasing brand name drugs over generics.